Sejahtera Surya Intrio is primarily engaged in pharmaceuticals activity. Its headquarters is located in Jawa Timur. The company was founded in 2005. Sejahtera Surya Intrio, a prominent player in the Indonesian pharmaceutical industry, was founded by a group of visionary entrepreneurs dedicated to improving healthcare access and quality in the region. The company focuses on the development, manufacturing, and distribution of a wide range of pharmaceutical products, including prescription medications, over-the-counter drugs, and health supplements. With a strong presence in Indonesia, Sejahtera Surya Intrio operates several branches across major cities, ensuring a robust local geographical footprint. The company is committed to expanding its reach and currently exports its products to several Southeast Asian countries, contributing to its growing global footprint. Sejahtera Surya Intrio's product portfolio includes well-known brands that cater to various therapeutic areas such as cardiovascular health, diabetes management, and respiratory care. The company is also actively involved in research and development to introduce innovative healthcare solutions. In collaboration with leading healthcare institutions and research organizations, Sejahtera Surya Intrio is part of several joint ventures aimed at advancing pharmaceutical research and development. The company is a member of key industry associations, which helps it stay at the forefront of industry trends and regulatory changes. Sejahtera Surya Intrio's mission is to enhance the quality of life through accessible and affordable healthcare solutions. The company envisions becoming a leader in the pharmaceutical industry by continuously innovating and adhering to the highest standards of quality and safety.
Headquarters
RT 002, RW 006
Surabaya; East Java;
Postal Code: 60284
Contact Details: Purchase the PT Sejahtera Surya Intrio report to view the information.
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service